Celldex Therapeutics Inc (NAS:CLDX)
$ 36.92 0.6 (1.65%) Market Cap: 2.43 Bil Enterprise Value: 1.61 Bil PE Ratio: 0 PB Ratio: 2.90 GF Score: 62/100

Celldex Therapeutics Inc - Phase 1b CIndU Interim Data Update Transcript

Mar 29, 2021 / 11:45AM GMT
Release Date Price: $20.47 (-13.81%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Celldex Interim Data Update Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Sarah Cavanaugh, Senior Vice President of Corporate Affairs. Thank you. Please go ahead, ma'am.

Sarah Cavanaugh
Celldex Therapeutics, Inc. - SVP of Corporate Affairs & Administration

Thank you. Good morning, and thank you all for joining us to discuss the exciting interim data set we reported earlier today from our Phase IB study of CDX-0159 in chronic inducible urticaria. With me on the call today from Celldex are Anthony Marucci, Co-Founder, President and CEO; Dr. Margo Heath-Chiozzi, Senior Vice President of Regulatory Affairs and Medical Lead on the study; Dr. Diane Young, Senior Vice President and Chief Medical Officer; Dr. Tibor Keler, Co-Founder, Executive Vice President and Chief Scientific Officer; and Dr. Diego Alvarado, Senior Director of Research and the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot